drugset
drugset / Trial / NCT03246880

Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients

NCT03246880 ↗

Phase 3 Completed 455 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.

Timeline

Start
2015-09
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral
Subject Tamsulosin Other / unclassified 0.2 mg Oral

Indications

benign prostatic hyperplasia